The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer

Baardwijk, Angela van; Dooms, Christophe; Suylen, Robert Jan van; Verbeken, Erik; Hochstenbag, Monique; Oberije, Cary; Rupa, D.; Pastoreková, Silvia; Stroobants, Sigrid; Buell, U.; Lambin, Philippe; Vansteenkiste, Johan; Ruysscher, Dirk De

doi:10.1016/j.ejca.2007.03.027

Cited by 185 publications

(137 citation statements)

References 24 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…In the three patients in whom an [ 18 F]FDG-PET scan was available, a good correlation was found between the hypoxic areas imaged with HX4 and the areas of high FDG uptake. This is consistent with the often observed relationship between tumour hypoxia and FDG uptake [9,10]. From the imaging perspective, there were some limitations inherent in the study design.…”

Section: Discussionsupporting

confidence: 86%

PET imaging of hypoxia using [18F]HX4: a phase I trial

Loon

Janssen

Öllers

et al. 2010

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Background and purpose Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers. In this phase I trial, we aimed to determine the toxicity of [ 18 F]HX4, a member of the 2-nitroimidazole family, at different dose levels. The secondary aim was to analyse image quality related to the HX4 dose and the timing of imaging. Methods Patients with a histologically proven solid cancer without curative treatment options were eligible for this study. A study design with two dose steps was used in which a single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [ 18 F]HX4 was injected. Toxicity was scored on day 0 and on days 3 and 7 after injection, according to the CTCAE 3.0 scoring system. PET/CT images of the largest tumour site were acquired 30, 60 and 120 min after injection. Results Six patients with stage IV carcinoma were included, four with non-small-cell lung carcinoma, one with thymus carcinoma, and one with colon carcinoma. No toxicity was observed in any of the patients at either dose level. The median tumour to muscle ratio 120 min after injection was 1.40 (range 0.63-1.98). Conclusion The findings of this study showed that [ 18 F] HX4 PET imaging for the detection of hypoxia is not associated with any toxicity. Imaging was successful; however, future trials are needed to determine the optimal image parameters.

show abstract

Section: Discussionsupporting

confidence: 86%

PET imaging of hypoxia using [18F]HX4: a phase I trial

Loon

Janssen

Öllers

et al. 2010

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

“…GLUT-1 expression is well correlated with 18 F-FDG uptake in several cancers [19][20][21][22]. However, recent contradictory studies reported that 18 F-FDG uptake in PTC was not correlated with GLUT-1 [1,3,23].…”

Section: Discussionmentioning

confidence: 99%

Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma

Lee

Han

Lee

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose The BRAF mutation, a potential prognostic factor in papillary thyroid carcinoma (PTC), is associated with a high expression of the glucose transporter gene. We investigated which clinicopathologic factors, including BRAF mutation status, influence 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) avidity. Methods We retrospectively reviewed 55 patients who underwent BRAF analysis from biopsy-confirmed PTC and 18 F-FDG positron emission tomography/computed tomography within 6 months before undergoing thyroid surgery from September 2008 to August 2014. Tumors were considered to be 18 F-FDG avid if the uptake was greater than that of the liver. 18 F-FDG uptake of PTCs was also analyzed semiquantitatively using SUV max . The association between 18 F-FDG avidity and clinicopathologic variables (age, tumor size, perithyroidal extension, cervical lymph node status, and BRAF mutation status) was investigated. Results Twenty-nine (52.7 %) of 55 patients had 18 F-FDGavid PTCs. PTCs with the BRAF mutation showed higher 18 F-FDG avidity (24/38, 63.2 %) than those without (5/17, 29.4 %). The BRAF mutation (p=0.025) and tumor size (p= 0.003) were significantly associated with 18 F-FDG avidity in univariate analysis, and the BRAF mutation status remained significant after adjusting for tumor size in multivariate analysis (p=0.015). In the subgroup of tumor size≥1 cm, the BRAF mutation was the only factor significantly associated with 18 F-FDG avidity (p=0.021). The mean SUV max of PTCs with the BRAF mutation was significantly higher than that of those without (4.89±6.12 vs. 1.96±1.10, p=0.039). Conclusions The BRAF mutation must be one of the most important factors influencing 18 F-FDG avidity in PTCs, especially in those with a tumor size≥1 cm.

show abstract

“…Tumour subtype is known to reflect the differential avidity of 18FDG uptake by cancer cells [21]. Glucose transporters mediate FDG uptake, and the expression of these proteins has been found to correlate with FDG uptake [22]. Moreover, the expression of glucose transporter type 1 (Glut-1) differed substantially between NSCLC of different histologies [23].…”

Section: Discussionmentioning

confidence: 99%

Studio comparativo con esame TC contrastografico e con PET-TC del tumore polmonare non a piccole cellule

et al. 2013

View full text Add to dashboard Cite

BackgroundPersonalized cancer therapy remains a challenge. In this context, we attempted to identify correlations between tumour angiogenesis, tumour metabolism and tumour cell type. To this aim, we used single=phase multidetector computed tomography (MDCT) and hybrid positron emission tomography-computed tomography (PET/CT) to determine whether net enhancement and standardized uptake value (SUVmax) were correlated with tumour size and cytology in patients affected by non-small cell lung cancer (NSCLC).Material/MethodsOur study included 38 patients (30 men, 8 women, mean age 70) with a NSCLC measuring between 3 cm and 7 cm, using a 16-slice multidetector CT (Brilliance Philips) and with PET-CT (Biograph 16 Siemens Medical Solutions). The following lesion parameters were evaluated: maximum diameter, medium density before contrast injection (CTpre), medium density after contrast injection (CTpost average), density in the most enhanced part of the lesion after contrast (CTpost max), net enhancement, SUVmax, age, and cytology. Correlation coefficient and p-value were computed for each pair of variables. In addition, correlations were computed for each pair of variables, and for all combinations of tumour types. We focused on subsets of data with more than 10 observations, and with correlation r>0.500 and p<0.05.ResultsA weak correlation (r=0.32; p=0.048) was found between SUVmax and tumour size; the correlation was stronger for masses larger than 31 mm (r=0.4515; p=0.0268). No other correlations were found among the variables examined.ConclusionsOur data may have prognostic significance, and could lead to more appropriate surgical treatment and better treatment outcome.

show abstract

The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer

Cited by 185 publications

References 24 publications

PET imaging of hypoxia using [18F]HX4: a phase I trial

PET imaging of hypoxia using [18F]HX4: a phase I trial

Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma

Studio comparativo con esame TC contrastografico e con PET-TC del tumore polmonare non a piccole cellule

Contact Info

Product

Resources

About